Iatrogenic Cushing's syndrome with inhaled fluticasone

Thomas Ledger^{1

2

2}, Winnie Tong^{1

2

2}, Janet Rimmer^{1

2

2}

Affiliations

Case Reports

Thomas Ledger et al. Aust Prescr. 2019 Aug.

. 2019 Aug;42(4):139-140.

doi: 10.18773/austprescr.2019.040. Epub 2019 Aug 1.

Thomas Ledger^{1

2

2}, Winnie Tong^{1

2

2}, Janet Rimmer^{1

2

2}

No abstract available

Keywords: Cushing’s syndrome; fluticasone furoate.

Conflict of interest statement

Conflict of interest: none declared

1. Therapeutic Goods Administration. Database of Adverse Event Notifications (DAEN) [Internet]. Canberra: Australian Government Department of Health; 2019. www.tga.gov.au/database-adverse-event-notifications-daen [cited 2019 Jul 1]
1. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing’s syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004;38:46-9. 10.1345/aph.1D222 - DOI - PubMed
1. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008;9:389-96. 10.1111/j.1468-1293.2008.00579.x - DOI - PubMed
1. Day RO, Snowden L, McLachlan AJ. Life-threatening drug interactions: what the physician needs to know. Intern Med J 2017;47:501-12. 10.1111/imj.13404 - DOI - PubMed